ABP 798
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for ABP 798, covering 2019-10-23 to 2019-10-23. Get the full timeline:
Most recent: Clinical Trial Update: Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab [Phase 3]